Genolution Inc is a Korea-based company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related to ribonucleic acid interference (RNAi) research. The Company is mainly engaged in the manufacture and sales of nucleic acid extraction reagents for extracting nucleic acids from human samples and automated nucleic acid extraction devices for automatically extracting nucleic acids from samples. The Company also provides RNAi services. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	₩1,296.00	-0.92%	31,959
30/07/26	₩1,308.00	+2.27%	24,294
29/07/26	₩1,279.00	-0.70%	83,156
28/07/26	₩1,288.00	-4.94%	19,790
27/07/26	₩1,355.00	+3.91%	34,286

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 31/07/2026			5-day change	1st Jan Change
1,296.00 ^KRW	-0.92%		-0.61%	-31.75%

02-19	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI

Market Cap	23.41B 16.29M 14.16M 13.18M 12.1M 22.85M 1.56B 23.21M 155M 60.98M 774M 61.18M 59.83M 2.6B	P/E 2024	-5.89x	P/E 2025	-2.95x
Enterprise Value	19.53B 13.59M 11.81M 10.99M 10.09M 19.06M 1.3B 19.36M 130M 50.86M 646M 51.03M 49.9M 2.17B	EV / Sales 2024	4.38x	EV / Sales 2025	3.23x
Free-Float	67.03%	Yield 2024 *	-	Yield 2025	-

02-19	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI
31/07/24	Genolution Inc. cancelled the transaction announced on May 7, 2024	CI
07/05/24	Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd. and another investor	CI
09/01/24	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
09/01/24	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
09/01/24	Genolution Inc.'s Equity Buyback announced on July 10, 2023, has expired with 477,003 shares, representing 2.59% for KRW 1,989.17 million.	CI
13/10/23	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
10/07/23	Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	CI
10/07/23	Genolution Inc. authorizes a Buyback Plan.	CI
15/05/23	Genolution Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
05/04/23	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI
05/04/23	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI

1 day	-0.92%
1 week	-0.61%
1 month	+2.86%
3 months	-31.36%
6 months	-30.73%
Current year	-31.75%

Genolution Inc. Stock

Stocks

A225220

KR7225220003

Biotechnology & Medical Research

Valuation: Genolution Inc.

Chart: Genolution Inc.

Latest news : Genolution Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Genolution Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,180	1,346
1 month	1,180	1,415
Current year	957	2,120
1 year	957	2,830
3 years	957	5,140
5 years	957	9,381.19
10 years	957	13,118.81

Manager	Title	Age	Since
Min-Ee Kim CEO	Chief Executive Officer	40	-
Ki-Ok Kim CEO	Chief Executive Officer	71	01/02/2006
Sang-Hoon Kim DFI	Director of Finance/CFO	66	-

Director	Title	Age	Since
Ki-Ok Kim BRD	Director/Board Member	71	01/02/2006
Hak-Soo Lee BRD	Director/Board Member	70	20/03/2020
Min-Ee Kim BRD	Director/Board Member	40	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/24/24 A	Sang-Hoon Kim	Others	Chief Financial Officer	404,000	2.1053%
5/19/24 A	Sang-Hoon Kim	Free	Chief Financial Officer	404,000	2.1053%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOLUTION INC.	-0.92%	-0.61%	-37.99%	-69.14%	16.29M
VERACYTE, INC.	-22.52%	-18.18%	+95.94%	+79.19%	3.72B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-6.66%	+1.35%	+118.49%	+183.54%	3.59B
CAREDX, INC.	+14.72%	+17.69%	+257.69%	+288.19%	2.26B
BGI GENOMICS CO., LTD.	+3.44%	+4.55%	-27.34%	-35.28%	2.17B
IOVANCE BIOTHERAPEUTICS, INC.	-13.22%	-18.44%	+51.87%	-43.31%	1.82B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-2.67%	-2.81%	+195.95%	-45.02%	969M
SEEGENE, INC.	+6.96%	-1.82%	-7.40%	+21.17%	853M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+1.29%	+6.41%	-38.87%	-11.36%	511M
CURIOX BIOSYSTEMS CO., LTD	+7.90%	-3.22%	-0.27%	-	449M
Average	-1.17%	-3.01%	+60.81%	+40.89%	1.64B
Weighted average by Cap.	-5.10%	-3.72%	+95.56%	+89.11%

	2024	2025
Net sales	7.14B 4.96M 4.32M 4.02M 3.69M 6.96M 474M 7.07M 47.35M 18.58M 236M 18.64M 18.24M 791M	9.4B 6.54M 5.69M 5.29M 4.86M 9.18M 625M 9.32M 62.4M 24.49M 311M 24.57M 24.03M 1.04B
Net income	-6.83B -4.75M -4.13M -3.84M -3.53M -6.66M -453M -6.77M -45.29M -17.78M -226M -17.83M -17.44M -757M	-11.64B -8.1M -7.04M -6.55M -6.02M -11.36M -773M -11.54M -77.25M -30.32M -385M -30.42M -29.75M -1.29B
Net Debt	-8.95B -6.23M -5.41M -5.04M -4.63M -8.73M -594M -8.87M -59.38M -23.31M -296M -23.38M -22.87M -992M	-3.89B -2.7M -2.35M -2.19M -2.01M -3.79M -258M -3.85M -25.78M -10.12M -128M -10.15M -9.93M -431M